Department of Internal Medicine II, Universitätsklinikum, Würzburg, Germany.
Baptist Cancer Center, Memphis, Tennessee, USA.
Clin Pharmacol Ther. 2019 Oct;106(4):781-791. doi: 10.1002/cpt.1396. Epub 2019 Mar 29.
Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single-agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single-agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.
单克隆抗体疗法是治疗血液系统恶性肿瘤的重要方法，但通常单药活性较低。然而，双特异性抗体将免疫细胞重新导向肿瘤以进行后续裂解，临床前和累积的临床数据支持这些药物在血液系统恶性肿瘤中的单药疗效，预示着新型双特异性药物开发的令人兴奋的时代的到来。本文讨论了该领域的最新进展，强调了为患者提供有效免疫疗法的挑战。
